Ribosome heterogeneity in tumorigenesis: the rRNA point of view

Virginie Marcel1,2, Frédéric Catez1,2, and Jean-Jacques Diaz1,2,*

1Centre de Recherche en Cancérologie de Lyon; UMR INserm 1052 CNRS 5286; Centre Léon Bérard; Lyon, France; 2Université de Lyon; Université Lyon 1; ISPB; Lyon, France

The "specialized ribosome" concept proposes that ribosome variants are produced and differentially regulate translation. Examples supporting this notion demonstrated heterogeneity of ribosomal protein composition. However, ribosome translational activity is carried out by rRNA. We, and others, recently showed that rRNA heterogeneity regulates translation to generate distinct translatomes promoting tumorigenesis.

Translation is one of the last steps of gene expression, during which ribosomes synthesize proteins. A growing body of evidence indicates that the translation process per se plays a key role in tumorigenesis. Significantly, it was recently revealed that components of the translational machinery play unexpected direct roles in tumorigenesis. For example, haploinsufficiency in ribosomal protein (RP) RPL24 is sufficient to significantly delay tumorigenesis in mice overexpressing the oncogene C-Myc or lacking the tumor suppressor phosphatase and tensin homolog (PTEN). In addition, it has been extensively demonstrated that the expression of oncogenes and tumor suppressors is regulated at the protein synthesis level. Finally, the specific inhibition of RNA polymerase I (RNA pol I) using small molecules selectively kills cancer versus healthy cells in mouse models.

Human ribosomes are composed of 80 ribosomal proteins and 4 ribosomal RNAs (rRNAs). Although ribosomes were shown to be effectors of translation 40 years ago, it only recently became apparent that they also act as regulators. First, during evolution, ribosomes of higher eukaryotes have extensively demonstrated that the expression of oncogenes and tumor suppressors is regulated at the protein synthesis level. Finally, the specific inhibition of RNA polymerase I (RNA pol I) using small molecules selectively kills cancer versus healthy cells in mouse models.

Human ribosomes are composed of 80 ribosomal proteins and 4 ribosomal RNAs (rRNAs). Although ribosomes were shown to be effectors of translation 40 years ago, it only recently became apparent that they also act as regulators. First, during evolution, ribosomes of higher eukaryotes have extensively demonstrated that the expression of oncogenes and tumor suppressors is regulated at the protein synthesis level. Finally, the specific inhibition of RNA polymerase I (RNA pol I) using small molecules selectively kills cancer versus healthy cells in mouse models.

Translation is one of the last steps of gene expression, during which ribosomes synthesize proteins. A growing body of evidence indicates that the translation process per se plays a key role in tumorigenesis. Significantly, it was recently revealed that components of the translational machinery play unexpected direct roles in tumorigenesis. For example, haploinsufficiency in ribosomal protein (RP) RPL24 is sufficient to significantly delay tumorigenesis in mice overexpressing the oncogene C-Myc or lacking the tumor suppressor phosphatase and tensin homolog (PTEN). In addition, it has been extensively demonstrated that the expression of oncogenes and tumor suppressors is regulated at the protein synthesis level. Finally, the specific inhibition of RNA polymerase I (RNA pol I) using small molecules selectively kills cancer versus healthy cells in mouse models.

Human ribosomes are composed of 80 ribosomal proteins and 4 ribosomal RNAs (rRNAs). Although ribosomes were shown to be effectors of translation 40 years ago, it only recently became apparent that they also act as regulators. First, during evolution, ribosomes of higher eukaryotes have extensively demonstrated that the expression of oncogenes and tumor suppressors is regulated at the protein synthesis level. Finally, the specific inhibition of RNA polymerase I (RNA pol I) using small molecules selectively kills cancer versus healthy cells in mouse models.

Keywords: fibrillarin, p53, RNA epigenetics, specialized ribosome, translation, tumorigenesis

Abbreviations: RNA pol I, RNA polymerase I; snRNA, small nucleolar RNA; RP, ribosomal protein; IRES, internal ribosome entry site

© Virginie Marcel, Frédéric Catez, and Jean-Jacques Diaz
*Correspondence to: Jean-Jacques Diaz; Email: jean-jacques.diaz@lyon.unicancer.fr

Submitted: 10/29/2014
Revised: 10/30/2014
Accepted: 10/31/2014

http://dx.doi.org/10.4161/23723556.2014.983755

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

www.tandfonline.com Molecular & Cellular Oncology 2:3, e983755; July/August/September 2015; Published with license by Taylor & Francis Group, LLC
structure and stability and can thus affect rRNA function. Interestingly, 60% of the 2'-O-methylation sites are within functional regions of rRNAs, and genetic studies in yeast have demonstrated that 2'-O-methylation is indeed important for the translational capacity of ribosomes.\(^7\) We reported for the first time that the rRNA 2'-O-methylation pattern modification is associated with changes in translational control during tumorigenesis.\(^8,9\) In immortalized human mammary epithelial cells (HMECs), p53 (TP53, best known as p53) knockdown using short hairpin RNA (shRNA) was associated with a modification of the rRNA 2'-O-methylation pattern. This p53-induced alteration in rRNA 2'-O-methylation pattern was linked to increased expression of FBL. We further demonstrated that FBL is a p53 target gene, whose expression is repressed following binding of p53 to the first intron of the FBL gene. Both an increase in FBL expression and modification of rRNA 2'-O-methylation pattern in HMECs-shp53 were associated with changes in the translational activity of ribosomes and in translational control. Reduced p53 expression induced, in an FBL-dependent manner, both a defect in translational fidelity (i.e., amino acid misincorporation and stop codon read-through) and increased translation of a subset of IRES-dependent translation of a subset of mRNAs encoding proteins that favor tumor development.

Our current model is that modulation of the rRNA 2'-O-methylation pattern induced by changes in FBL expression promotes the translation of a subset of mRNAs encoding proteins with oncogenic properties, which favors tumor initiation and progression (Figure 1). This view is supported by additional observations. We reported that FBL overexpression promotes anchorage-independent cell proliferation and chemoresistance of MCF-7 breast cancer cells.\(^9\) Moreover, in breast cancers, a high level of FBL appeared to be an independent marker of poor prognosis, supporting the importance of maintaining a reduced level of FBL to prevent tumorigenesis.\(^8\) Following our publication, the Kouzarides group identified FBL as the methyl-transferase that catalyzes methylation of Q105 of histone H2A, a novel histone post-translational modification found to be highly enriched in rDNA chromatin, and enhances RNA pol I activity.\(^10\) Together, these data support an important role of FBL in controlling not only ribosome quality, but also ribosome quantity that impacts tumorigenesis.

The significance of the rRNA perspective in the heterogeneity of ribosomes also has roots in studies of rRNA pseudo-uridylation since mutation of dyskerin (DKC1), the enzyme catalyzing this modification, alters IRES-dependent translation and is associated with cancer susceptibility.\(^1\) In the near future the different rRNA chemical modifications will have to be analyzed in concert since the rRNA domains critical for translational activity contain all of the chemical modifications identified to date in rRNA. One must therefore wonder whether the impact of rRNA chemical modifications on translation should be considered RNA epigenetic regulations, as for modification of other classes of RNA and for DNA epigenetics.\(^6\) However, several key questions remain to be addressed, including “Are rRNA chemical modifications heritable?” and “Do enzymes exist that are able to demethylate or de-pseudo-uridylate rRNA to dynamically regulate the system?”

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Figure 1. Impact of rRNA 2'-O-methylation on translation and cellular malignant phenotype. Compared to healthy cells (green panel), cancer cells (red panel) express higher levels of fibrillarin (FBL), which promotes an increase in the amount of ribosomes and changes the ribosomal (rRNA) 2'-O-methylation pattern. Alteration of rRNA composition reduces the translational fidelity and enhances internal ribosome entry site (IRES)-dependent translation of a subset of mRNAs encoding proteins that favor tumor development.
Funding
This work was supported by CNRS, INSERM, Université Claude Bernard Lyon-1, Center Léon Bérard, Fondation ARC pour la Recherche sur le Cancer (n° SFI20121205802), Ligue Nationale Contre le Cancer Comité Rhône-Alpes-Auvergne et Saône et Loire (n°13-763C) and ANR (13-BSV8-0012-01 Ribometh). VM and JJD are members of Inserm. FC is a member of CNRS.

References
1. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 2013; 5(2): a012336; PMID:23767671; http://dx.doi.org/10.1101/cshperspect.a012336
2. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10:254-66; PMID:20332778; http://dx.doi.org/10.1038/nrc2824
3. Peltonen K, Colas I, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Luiho M. A targeting modality for destruction of RNA polymerase I that possesses anticaner activity. Cancer Cell 2014; 25:77-90; PMID:24434211; http://dx.doi.org/10.1016/j.ccr.2013.12.009
4. Anger AM, Armache JP, Berninghausen O, Habeck M, Subklewe M, Wilson DN, Beckmann R. Structures of the human and Drosophila 80S ribosome. Nature 2013; 497:80-5; PMID:23636399; http://dx.doi.org/10.1038/nature12104
5. Xue S, Barna M. Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nat Rev Mol Cell Biol 2012; 13:355-69; PMID:22617470; http://dx.doi.org/10.1038/nrm3559
6. Therizols G, Lafontes F, Marcel V, Cazes F, Bouvet P, Diaz JJ. Ribosomal methylation and cancer. Translational Epigenetics Series, In press.
7. Decatur WA, Fournier MJ. rRNA modifications and ribosome function. Trends Biochem Sci 2002; 27:344-51; PMID:12114023; http://dx.doi.org/10.1016/S0968-0004(02)02109-6
8. Marcel V, Ghayad SE, Belin S, Therizols G, Morel AP, Solano-Gonzalez E, Vendrell JA, Hacot S, Mertani HC, Alharer MA, et al. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell 2013; 24:318-30; PMID:24029231; http://dx.doi.org/10.1016/j.ccr.2013.08.013
9. Belin S, Beghin A, Solano-Gonzalez E, Bezin I, Brunet-Manquat S, Textorius J, Prats AC, Mertani HC, Dumonter C, Diaz JJ. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PloS One 2009; 4:e7147; PMID:19779612; http://dx.doi.org/10.1371/journal.pone.0007147
10. Tessarz P, Santos-Rosa H, Robson SC, Sylvestersen KB, Nelson CJ, Nielsen ML, Kouzarides T. Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification. Nature 2014; 505:564-8; PMID:24352239; http://dx.doi.org/10.1038/nature12819